Download the Complete Report Here
By Brandon Hornback
Aurora Hashish Inc. (NASDAQ: ACB) smoked one other quarter, led by top-line development, profitability, and disciplined capital allocation. And in recent information, there’s optimistic money circulation proper across the nook.
Take successful off this: The highest line elevated 11%, pushed primarily by robust medical hashish efficiency linked to excessive demand from Germany, Poland, and Australia. Gross margin expanded considerably to 61%, led by the medical enterprise, which continues to outperform the broader hashish trade.
Administration expects a return to optimistic free money circulation in its fiscal third quarter, which ends in December. Moreover, ACB maintains a rock-solid steadiness sheet with C$142 million in money, and no cannabis-related debt.
To high it off, the re-certification of Aurora’s EU-GMP and Leuna facility enlargement has positioned Aurora amongst a brief listing of hashish firms, providing visibility for sustainable development and margin enchancment.
Turning to valuation, ACB is buying and selling at 0.9x ahead gross sales and 6.5x EV/EBITDA, under peer averages even amid a pretty trade positioning. For buyers serious about a simple play on medical and worldwide hashish markets, ACB is a reputation to maintain on the shelf.
Obtain the total report back to be taught extra about Aurora’s transformation from turnaround story to trailblazer.
Download the Complete Report Here
Read Exec Edge’s Initiation on Aurora Here
Subscribe to our Weekly Newsletter to Receive All Research
Contact:
